This combination treatment led to an increase in the expression of macrophage-colony stimulating factor (M-CSF), IL-1, and IFNAR, potentially promoting macrophage proliferation, differentiation, and activation in the tumour microenvironment. The gene discussed is CSF1; the disease is neoplasm.